TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ADC Therapeutics ( (ADCT) ) has provided an announcement.
On December 3, 2025, ADC Therapeutics announced updated results from its LOTIS-7 Phase 1b trial, which evaluates the combination of ZYNLONTA® and glofitamab in patients with relapsed or refractory diffuse large B-cell lymphoma. The trial showed a high overall response rate of 89.8% and a complete response rate of 77.6%, with strong efficacy in both relapsed and primary refractory populations. The treatment was generally well tolerated, with manageable safety concerns, highlighting its potential impact on the company’s therapeutic offerings and market positioning.
The most recent analyst rating on (ADCT) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on ADC Therapeutics stock, see the ADCT Stock Forecast page.
Spark’s Take on ADCT Stock
According to Spark, TipRanks’ AI Analyst, ADCT is a Neutral.
ADC Therapeutics’ overall stock score is primarily impacted by its financial instability and negative valuation metrics. While there are promising clinical developments and strategic initiatives, these are overshadowed by persistent financial challenges and bearish technical indicators.
To see Spark’s full report on ADCT stock, click here.
More about ADC Therapeutics
ADC Therapeutics SA operates in the biotechnology industry, focusing on the development of antibody-drug conjugates for the treatment of hematological cancers and solid tumors.
Average Trading Volume: 1,083,911
Technical Sentiment Signal: Buy
Current Market Cap: $438.5M
For a thorough assessment of ADCT stock, go to TipRanks’ Stock Analysis page.